Chimerix's Brincidofovir Shows Potential Survival Benefit

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Chimerix's Brincidofovir Shows Potential Survival Benefit in Adenovirus Infection

DURHAM, N.C., Oct. 8, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX ), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, announced today preliminary data for its investigational antiviral brincidofovir (BCV, CMX001) showing improved survival for patients with adenovirus in the open-label pilot portion of the Phase 3 AdVise Trial. These data will be presented at the annual meeting of the Infectious Diseases Society of America (IDSA), IDWeek, on Saturday, October 11 at 10:50 a.m. EDT in Philadelphia, PA.

The preliminary survival analysis data, based on 48 evaluable patients from the ongoing AdVise Trial, showed a mortality rate of 35 percent compared with the historic rates of up to 80 percent mortality in the first month after diagnosis. A majority of subjects also had suppression or clearance of adenovirus from the blood. There is currently no approved treatment for adenovirus, an infection that can progress rapidly in patients with a weakened immune system due to disease or medications. 

"When progressive adenovirus infection occurs in immunocompromised patients, they deteriorate, and the infection can be fatal in up to four of every five cases," said Dr. Jo-Anne Young, Professor of Medicine and Medical Director of the Program in Transplant Infectious Disease at the University of Minnesota. "In these very sick patients who were treated with brincidofovir, nearly two-thirds of the patients survived the first few weeks when we have historically seen the highest mortality. These results are encouraging and warrant the continued evaluation of brincidofovir as a promising antiviral for this life-threatening infection, for which a treatment is desperately needed."

Chimerix initiated AdVise in March 2014 based on potency observed in vitro and on clinical data from a Phase 2 trial and a large expanded access trial which showed the potential for improved clinical outcomes. As of September 19 th , 48 subjects had enrolled in AdVise, with 35 percent mortality observed to date (17 of 48) with a median duration of observation of 57 days for living patients.

The trial is enrolling pediatric and adult patients with adenovirus infection who receive brincidofovir twice weekly for twelve weeks. Baseline information and at least two months of follow up are available for 26 subjects. Of those 26 patients, 23 had measurable viral loads at study entry, and three patients had no virus detectable in the blood but had diagnosed adenovirus infection. Fourteen of the 23 patients with viremia at study entry achieved undetectable viral loads during treatment. Twelve of the 26 patients died.

Over half of the subjects were hematopoeitic cell transplant (HCT) recipients with disseminated disease, but solid organ transplant recipients and patients undergoing chemotherapy were also enrolled. Over one-third of the subjects (10 of 26) had a second active infection with another DNA virus in addition to adenovirus, including BK virus (27 percent), cytomegalovirus (19 percent) and Epstein Barr virus (8 percent).

The safety and tolerability profile of brincidofovir in these initial subjects was similar to other studies of brincidofovir in immunocompromised patients with complicated medical issues, with only three subjects discontinuing due to adverse events. Of the six subjects who enrolled in the study with adenovirus-related diarrhea, three reported improvement of symptoms and three remained stable.

"These data reinforce the potential for brincidofovir to significantly impact the mortality from adenovirus infections and provide data to support the design of the pivotal trial," said W. Garrett Nichols, M.D., M.S., Chief Medical Officer of Chimerix. "It is also important that, particularly in patients who are struggling with adenovirus infection, more than one-third of patients have more than one DNA virus, which underscores the need for a safe and broad-spectrum antiviral."

About AdVise

AdVise is a Phase 3 clinical trial to evaluate the safety and efficacy of brincidofovir for the treatment of adenovirus infection. In March 2014, Chimerix initiated the open-label pilot portion of the study. Chimerix is working closely with the U.S. Food and Drug Administration (FDA) on the design of a pivotal Phase 3 study that will be a continuation of this pilot study. Adenovirus infection can be associated with a mortality rate of up to 80 percent in patients who are undergoing hematopoeitic cell transplants (HCT), and there are no therapies approved to treat this infection. Adenovirus causes upper respiratory infections, including the common cold in individuals with a functional immune system, but it can lead to graft failure, severe pneumonia, hepatitis or death in those with a weakened immune system, such as patients who have undergone a transplant.   

About Brincidofovir (BCV, CMX001)

Chimerix's lead product candidate, brincidofovir, is an oral nucleotide analog that has shown in vitro antiviral activity against all five families of DNA viruses that affect humans, including viruses in the herpes virus family and adenovirus. Brincidofovir has not been associated with kidney or bone marrow toxicity in nearly 900 patients treated to date, side effects that can be treatment limiting with currently available antivirals. Building on the positive Phase 2 results in cytomegalovirus (CMV) prevention, Chimerix initiated the Phase 3 SUPPRESS trial in 2013. If positive, data from SUPPRESS will support Chimerix's initial regulatory submission for brincidofovir for the prevention of CMV infection in adult hematopoietic cell transplant (HCT) recipients. Chimerix recently initiated AdVise, a Phase 3 trial in adenovirus, which is an often-fatal viral infection with no approved treatment; enrollment is ongoing for the pilot portion of the trial. Chimerix is also working with the Biomedical Advanced Research and Development Authority (BARDA) to develop brincidofovir as a medical countermeasure against smallpox. Brincidofovir has received Fast Track designation from the FDA for CMV, adenovirus, and smallpox.  

About Chimerix

Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals in areas of high unmet medical need. Chimerix's proprietary technology has given rise to brincidofovir (BCV, CMX001), a clinical-stage nucleotide analog lipid-conjugate, which has demonstrated potent antiviral activity and safety in convenient, orally administered dosing regimens. Chimerix is currently enrolling SUPPRESS, the Phase 3 study of brincidofovir for the prevention of cytomegalovirus (CMV) in hematopoietic cell transplant recipients. In addition, Chimerix is enrolling the pilot portion of the Phase 3 AdVise study of brincidofovir for treatment of adenovirus infection. Chimerix is also working with BARDA to develop brincidofovir as a medical countermeasure against smallpox. For further information, please visit Chimerix's website, www.chimerix.com .  

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Chimerix's filings with the Securities and Exchange Commission, including without limitation its most recent Quarterly Report on Form 10-Q, its most recently filed Current Reports on Form 8-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Chimerix undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Joseph T. Schepers Executive Director, Investor Relations and Corporate Communications 919-287-4125

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Philadelphia Firm Targets 100 Toys for Children This Holiday

Updated Category News Views 54

A hundred unopened toys can look modest on paper, yet that is exactly why this Philadelphia effort lands differently than the usual chest-thumping corporate charity chatter. van der Veen, Hartshorn & Levin has set a clear holiday target: collect 100 new, unwrapped toys for children in the Philadelphia area through the U.S. Marine Corps Reserve Toys for Tots program. No...

Continue Reading
Portillo's Faces Legal Heat: Investor Class Action Filed

Updated Category News Views 250

What’s Eating Portillo's? Ah, once upon a misstep in the land of promising expansion, now we have Portillo's Inc. (NASDAQ: PTLO) neck-deep in legal hot water. Those golden fries and famous sandwiches somehow didn't pave the way for stockholder bliss. Why the turmoil? On an ordinary November morning, the DJS Law Group made it clear: They're rallying the troops for a...

Continue Reading
AR Cards in Casino Gaming: A High-Stakes Revolution

Updated Category News Views 106

A New Breed of Casino Experience Walk into a casino today, and you might just enter a whole new reality. No, this isn’t a cheesy magician’s trick or a glitzy PR stunt—this is the real deal brought to you by augmented reality (AR) trading cards. Imagine the slots you love wrapped in a sci-fi movie where characters leap out, tap you on the shoulder, and call you by...

Continue Reading
LA Auto Show 2026: Thrills, Games, and Cars Galore

Updated Category News Views 82

A Family Day Like No Other at the LA Auto Show Kicking into gear this November, the 2026 Los Angeles Auto Show puts the pedal to the metal for families seeking a full day of fun without breaking the bank. We're talking about 10 solid days where auto-mania meshes with interactive experiences, all nestled in the Los Angeles Convention Center. Whether you're a gearhead or a...

Continue Reading
Texxon Faces Revenue Slide Amid Strategic Shifts

Updated Category News Views 176

Texxon's Strategic Transitions and Financial Headaches Texxon Holding Limited (NASDAQ:NPT) just laid their cards on the table, unveiling a mixed bag in their fiscal year 2026 results. As the world's chemical and plastics scene faces winds of change, Texxon buckled down and tried to steer the ship clear from the rocks. It's a balancing act juggling market headwinds, a new...

Continue Reading
PEGATRON Unveils AI and HPC Advances at SC26

Updated Category News Views 106

Revamping AI with High-Density Computing You know, back in the day, AI was just about training models and running basic inference. But now, it's all about these crazy agentic AI tasks—autonomous agents doing things I couldn't have imagined. PEGATRON's Evolution in Infrastructure PEGATRON's latest move at SC26 is a real leap forward in this ongoing AI saga. They're...

Continue Reading
Shareholder Alert: Investigation Looms Over GDYN

Updated Category News Views 103

Grid Dynamics Under Legal Scrutiny There’s nothing quite like waking up to find your pick embroiled in an investigation. Grid Dynamics Holdings, Inc. (NASDAQ: GDYN) is on the radar, with law firm Levi & Korsinsky diving headfirst into potential infractions of fiduciary duties by some of the company’s top brass. The Lowdown on the Investigation This whole circus was...

Continue Reading
Triple Crossing Tests a Tough Inland Marine Market

Updated Category News Views 0

Inland marine is where tidy insurance appetites go to get bent out of shape. A contractor’s rented machine, cargo moving between points, a half-finished building, or equipment that is neither parked forever nor easy to classify can turn a standard quote into a week of broker phone calls. Triple Crossing Specialty is stepping directly into that mess, launching a new...

Continue Reading
Operation Healing Forces Partners with Wounded Warrior

Updated Category News Views 80

Joining Forces for Special Operations Families When it comes to the heavy lifting of supporting Special Operations Forces (SOF) families, two powerhouses—Operation Healing Forces (OHF) and Wounded Warrior Project (WWP)—are doubling down. They’re not just tossing around good intentions. Oh no, they’re pulling out the stops with a solid partnership focused on...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 359

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionary Gene Therapy Brings Hope to Young Patients

Updated Category News Views 279

Transformative Journey of Gene Therapy for AADC Deficiency Laughter and joy filled the sunny lobby of a research clinic, where a spirited little boy named Sriansh Ojha played happily with his sister, marking a dramatic contrast to his early life struggles. This remarkable transformation is largely due to gene therapy, a groundbreaking treatment that has changed the...

Continue Reading
Damon Inc. Unveils $30 Million Equity Offering for Mobility Innovation

Updated Category News Views 224

Introduction to Damon's Innovative Strategy Damon Inc. has recently announced a substantial $30 million Regulation A+ equity offering, which is set to enhance its impressive lineup of personal mobility products. The company, renowned for its electric motorcycles, aims to leverage the proceeds not only to fuel innovation in its products but also to fortify its...

Continue Reading
Cindy Eckert: Shaping the Future of Women's Health Together

Updated Category News Views 375

Cindy Eckert's Impact on Women's Health Innovation Cindy Eckert, the remarkable Founder and CEO of Sprout Pharmaceuticals, has been announced as the keynote speaker for the highly anticipated Women's Health Summit at Harvard Business School. This significant event, scheduled for 2025, aims to unite leaders, investors, and innovators dedicated to transforming women's...

Continue Reading
VoiceBrain and Diga-Talk Forge Partnership to Enhance Communications

Updated Category News Views 270

VoiceBrain and Diga-Talk Solutions Collaborate for Innovation In a groundbreaking partnership, VoiceBrain, renowned for its AI voice analytics, has teamed up with Diga-Talk Solutions, specialists in Push-to-Talk (PTT) over cellular technology. This exciting collaboration was unveiled during a prominent industry event, aiming to revolutionize real-time communication across...

Continue Reading
AstaReal's Research Reveals Astaxanthin Benefits for Kids' Eyes

Updated Category News Views 234

AstaReal's Groundbreaking Research on Astaxanthin AstaReal, Inc. has made a significant advancement in understanding children's eye health with its innovative research on astaxanthin. This powerful antioxidant, derived from the microalgae Haematococcus pluvialis, has been recognized globally for its benefits in enhancing visual performance, particularly in adults....

Continue Reading